Dr JAY K. SHETH

Scopus Publications

An Objective Overview of Covid19 Vaccine Situation in India
Jay Sheth, Kshem Prasad, Tapasvi Puwar
National Journal of Community Medicine, 2022
Entire world was eagerly waiting for the vaccine against SARS-CoV2 ever since Covid19 pandemic started. India is the second largest populous nation and is among the very few nations who has developed a vaccine against SARS-CoV2. India is also a major vaccine producing hub supplying large quantum of vaccines to the rest of the world. Efficacy, advantages and comparison between various covid vaccine has been largely discussed by the scientific community. However, there are various other factors affecting the vaccine situation in a nation, may it be the plan, strategy, it’s implementation, local context, health infrastructure etc. While there are many news and views related to covid-19 vaccine, one need to look beyond & into so many other aspects related to the factors affecting this situation. Through discussion of some of these key factors, we tried to draw an overall picture of the Covid19 vaccine situation in India. Keeping in line with our objective, we keep the focus of our discussion on vaccine development & manufacturing issues, diplomatic decisions on vaccine & the reasons behind the same, international factors etc. We have purposefully restricted our discussion to these factors and did not go in details of the national level policy and its implementation details in this article.
Seroprevalence of Immunoglobulin G Antibody among Contacts of COVID-19 Cases: A Study from India
Om Prakash, Bhavin Solanki, Jay Sheth, Mehul Acharya, Mina Kadam, Sheetal Vyas, Aparajita Shukla, Hemant Tiwari
Journal of Health Science and Medical Research, 2022
Objective: To estimate Covid19 seropositivity among contacts of cases and to compare the seropositivity among different types of contact for assessing the differential risk & transmission dynamics.Material and Methods: A large-scale population-based serosurvey was carried out among the general population of Ahmedabad during the second half of October 2020. The contacts of cases were selected based on the population proportion and enrolled as an additional category. The seropositivity among the contacts was estimated using the enzyme-linked immunosorbent assay and compared with different types of contact and available demographic factors.Results: As of October 2020, the seropositivity against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV2) among contacts of cases in Ahmedabad was 26.0% [95% confidence interval 24.2–28.0]. The seropositivity among family contacts was significantly higher (28.8%) compared to other contacts (24.4%) (Z=2.19, p-value=0.028). This trend was seen across all age groups and both sexes. The seropositivity was higher among females (27.7%) compared to males (24.5%) but the difference was statistically not significant (Z=1.64, p-value=0.101). In terms of age groups, the positivity had an increasing trend up to 60 years but declined after that.Conclusion: A seropositivity of 26.0% among contacts indicates that a large proportion of contacts demonstrated Immunoglobulin-G antibodies. This highlights asymptomatic transmission and/or low sensitivity of the diagnostic tests. The current strategy for contact tracing and testing among contacts is justified based on the significantly higher seropositivity among family contacts.
SARS-CoV2 IgG antibody: Seroprevalence among health care workers
Om Prakash, Bhavin Solanki, Jay Sheth, Govind Makwana, Mina Kadam, Sheetal Vyas, Aparajita Shukla, Jayshri Pethani, Hemant Tiwari
Clinical Epidemiology and Global Health, 2021
Background Health Care Workers (HCWs) are at higher risk for Covid19. Sero-surveillance among HCWs using IgG antibodies can add further value to the scientific findings. Objectives To estimate seropositivity among HCWs and to correlate it with various factors affecting seropositivity. Methods Population based large scale sero-surveillance among HCWs was carried out during second half of August’20 in Ahmedabad using “Covid-Kavach” IgG Antibody Detection ELISA kits. Seropositivity among HCWs was estimated and compared with various demographic & other factors to understand their infection & immunity status. Proportions and Z-test were used as appropriate. Results As on August’20, Seropositivity among HCWs from Ahmedabad is 23.65% (95% Confidence Interval 21.70–25.73%). Seropositivity of 25.98% (95%CI 23.47–28.66) among female HCWs is significantly higher than 19.48% (95%CI 16.53–22.80) among male HCWs. The zone wise positivity among HCWs closely correlate with cases reported from the respective zone. The sero-positivity among HCWs from the earliest and worst affected zones have lower level of seropositivity as compared to the zones affected recently. This might be pointing towards the fact that the IgG Antibodies may not be long lasting. Conclusion As on August 2020, the seropositivity of 23.65% in HCWs indicate high level of disease transmission and higher risk of infection among HCWs in Ahmedabad. The seropositivity is significantly higher among female HCWs. Zone wise seropositivity, closely correlate with the reported cases from the respective zone. Their comparison also indicates the possibility of reducing IgG seropositivity, which necessitates further in-depth scientific research to generate greater scientific evidences.
Serosurveillance among covid-19 cases in ahmedabad using sars-cov2 igg antibodies
Om Prakash, Bhavin Solanki, Jay Sheth, Daxa Maitrak, Mina Kadam, et al.
Indian Journal of Community Health, 2021
Background: Serosurveillance study focusing on antibodies against SARS-CoV2 among the Covid19 cases can add value in the scientific knowledge & help in formulating valid predictions regarding immunity status in the post-covid period. Objectives: To estimate seropositivity among covid19 cases and to identify various factors affecting seropositivity. Methods: During second half of October 2020, a population based serosurvey on Covid19 cases was carried out in Ahmedabad. Covid-Kavach test kits were used and estimated seroprevalence was compared with available demographic and covid19 case related parameters to identify factors affecting seropositivity in the post-covid period. Simple proportions and Z-test were used as appropriate. Results: As on October 2020, the sero-positivity among Covid19 cases in Ahmedabad was 54.51% [95% Confidence Interval (CI) 52.14-56.86%]. Females have higher positivity (54.78%) as compared to males (54.30%) but the difference was statistically not significant (Z=0.19, P=0.84). Among children and elderly, the positivity is high and from young adults to elderly the seropositivity has an increasing trend. Severity of clinical illness and longer duration of hospitalization are associated with higher seropositivity. Conclusion: With 54.51% seropositivity among covid19 cases, it is clear that all the covid19 cases may not have developed IgG antibodies, have undetectable level or might have disappeared during the post-covid period. Comparison of seropositivity with age group and clinical case details clearly suggest close correlation with the severity of clinical symptoms. The seronegative cases indicate the need for further in-depth scientific research to identify the factors affecting immunity and to uncover the reasons behind the same.
COVID-19 serosurveillance positivity in general population: Comparison at different times
Om Prakash, Bhavin Solanki, Jay Sheth, Chirag Shah, Mina Kadam, Sheetal Vyas, Aparajita Shukla, Hemant Tiwari
National Journal of Community Medicine, 2021
Introduction: Serological surveys estimating the cumulative incidence of the disease are powerful and effective tools for monitoring the epidemic and in determining the immunity status. Objectives: To compare the percentage sero-positivity for IgG antibodies against SARS-CoV2 at two different time period in the same population to understand the pandemic and predict about the immunity status of the population. Methods: As a part of Covid19 pandemic management, two separate population based sero-survey within a gap of 1½ months were carried in Ahmedabad city to scientifically document the progress of the Covid19 pandemic. Various demographic factors and other parameters from both the survey were compared with seropositivity for valid and precise estimation of disease situation as well as immunity status of the population. Results: The study documents an increase in seropositivity by 5.32% (from 17.92% to 23.24%). The seropositivity shows increasing trend with increase in the age group and the seropositivity is significantly higher among females. Overall higher seropositivity against the reported cases in the first sero-survey and the narrow increase in the seropositivity during the subsequent sero-survey inspite of high number of cases may indicate temporary status of the antibodies. This may also be due to the difference in the level of stigma, health care service delivery, service utilization and related field level situation affecting the asymptomatic/unreported case positivity. Conclusion: The result of seropositivity comparison indicates the scopes for further research to confirm and generate greater evidences regarding the factors affecting seropositivity.
Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: A cross-sectional study
Om Prakash, Bhavin Solanki, Jay K Sheth, Bhavin Joshi, Mina Kadam, Sheetal Vyas, Aparajita Shukla, Hemant Tiwari, Sanjay Rathod, Anil Rajput, Toral Trivedi, Vaibhav Ramanuj, Anand Solanki
BMJ Open, 2021
ObjectivesTo study the percentage seropositivity for SARS-CoV-2 to understand the pandemic status and predict the future situations in Ahmedabad.Study designCross-sectional study.SettingsField area of Ahmedabad Municipal Corporation.ParticipantsMore than 30 000 individuals irrespective of their age, sex, acute/past COVID-19 infection participated in the serosurvey which covered all the 75 Urban Primary Health Centres (UPHCs) across 48 wards and 7 zones of the city. Study also involved healthcare workers (HCWs) from COVID-19/non-COVID-19 hospitals.InterventionsSeropositivity of IgG antibodies against SARS-CoV-2 was measured as a mark of COVID-19 infection.Primary and secondary outcomesSeropositivity was used to calculate cumulative incidence. Correlation of seropositivity with available demographic detail was used for valid and precise assessment of the pandemic situation.ResultsFrom 30 054 samples, the results were available for 29 891 samples and the crude seropositivity is 17.61%. For all the various age groups, the seropositivity calculated between 15% and 20%. The difference in seropositivity for both the sex group is statistically not significant. The seropositivity is significantly lower (13.64%) for HCWs as compared with non-HCWs (18.71%). Seropositivity shows increasing trend with time. Zone with maximum initial cases has high positivity as compared with other zones. UPHCs with recent rise in cases are leading in seropositivity as compared with earlier and widely affected UPHCs.ConclusionsThe results of serosurveillance suggest that the population of Ahmedabad is still largely susceptible. People still need to follow preventive measures to protect themselves till an effective vaccine is available to the people at large. The data indicate the possibility of vanishing immunity over time and need further research to cross verify with scientific evidences.
Severe acute respiratory syndrome coronavirus 2 immunoglobulin G antibody: Seroprevalence among contacts of COVID-19 cases
Om Prakash, B. Solanki, Jay K Sheth, Mina Kadam, S. Vyas, Serosurveillance Research TeamFNx01
Indian Journal of Public Health, 2021
Background: Multiple serosurveillance studies have focused on the presence of antibodies against severe acute respiratory syndrome coronavirus 2 in the general population and confirmed cases. However, seroprevalence of immunoglobulin G (IgG) among contacts of confirmed cases can add further value to the scientific findings. Objectives: The objective is to estimate COVID-19 seropositivity among contacts of COVID-19 cases and to compare the seropositivity between types of contact for the assessment of differential risk and transmission dynamics. Methods: Large scale population-based serosurveillance on contacts of COVID-19 cases was carried out during the second half of August 2020 in Ahmedabad using the COVID-Kavach. The seropositivity among contacts was estimated and correlated-compared with type of contact and other demographic factors. Results: With 1268 positive for IgG antibodies from 3973 samples, the seropositivity against COVID-19 among contacts of cases in Ahmedabad was 31.92% (95% confidence interval 30.48%–33.38%). The seropositivity among family contacts was significantly higher (39.36%) as compared to other contacts (28.72%) (Z = 6.60, P < 0.01). This trend is seen across all age groups and both the sex groups. The seropositivity has increasing trend with increasing age and is significantly higher among females (35.11%) than males (28.95%) (Z = 4.16, P < 0.01). Conclusion: Seropositivity of 31.92% among contacts indicates that a large proportion of contacts have already acquired immunity on account of their contact with the case. Higher seropositivity among family contacts justifies the risk categorization and testing strategy adopted for the contacts of the cases. This also reaffirms the need for contact tracing strategy for controlling the inevitable spread of pandemic.
Divergent trends in ischaemic heart disease and stroke mortality in India from 2000 to 2015: a nationally representative mortality study
Calvin Ke, Rajeev Gupta, Denis Xavier, Dorairaj Prabhakaran, Prashant Mathur, Yogeshwar V Kalkonde, Patrycja Kolpak, Wilson Suraweera, Prabhat Jha, Shazia Allarakha, Dharmappa Basavarajappa, Vikas Dhimar, Harsh Jaiswal, Shrikant Kalaska, Geetha Memon, Saritha Nair, Vishnu Rao, Reeta Rasaily, Damodar Sahu, Shweta Sharma, Deepak Kumar Shukla, Jitenkumar K. Singh, Lucky Singh, Anju Sinha, Shally Awasthi, Jayant K. Banthia, Rajesh Dikshit, Rajesh Kumar, J.S. Thakur, Faujdar Ram, Usha Ram, Jay Sheth, George D'Souza, Rehana Begum, Denis Xavier, Rajeev Gupta, Hellen Gelband, Prabhat Jha, Calvin Ke, Patrycja Kolpak, Wilson Suraweera, Yogeshwar V. Kalkonde, Prashant Mathur, Dorairaj Prabhakaran
Lancet Global Health, 2018
Summary Introduction India accounts for about a fifth of cardiovascular deaths globally, but nationally representative data on mortality trends are not yet available. In this nationwide mortality study, we aimed to assess the trends in ischaemic heart disease and stroke mortality over 15 years using the Million Death Study. Methods We determined national and subnational cardiovascular mortality rates and trends by sex and birth cohort using cause of death ascertained by verbal autopsy from 2001 to 2013 among 2·4 million households. We derived mortality rates for ischaemic heart disease and stroke by applying mortality proportions to UN mortality estimates for India and projected the rates from 2000 to 2015. Findings Cardiovascular disease caused more than 2·1 million deaths in India in 2015 at all ages, or more than a quarter of all deaths. At ages 30–69 years, of 1·3 million cardiovascular deaths, 0·9 million (68·4%) were caused by ischaemic heart disease and 0·4 million (28·0%) by stroke. At these ages, the probability of dying from ischaemic heart disease increased during 2000–15, from 10·4% to 13·1% in men and 4·8% to 6·6% in women. Ischaemic heart disease mortality rates in rural areas increased rapidly and surpassed those in urban areas. By contrast, the probability of dying from stroke decreased from 5·7% to 5·0% in men and 5·0% to 3·9% in women. A third of premature stroke deaths occurred in the northeastern states, inhabited by a sixth of India’s population, where rates increased significantly and were three times higher than the national average. The increased mortality rates of ischaemic heart disease nationally and stroke in the northeastern states were higher in the cohorts of adults born in the 1970s onwards, than in earlier decades. A large and growing proportion of the ischaemic heart disease nationally and stroke deaths in high-burden states reported earlier diagnosis of cardiovascular disease, but low medication use. Interpretation The unexpectedly diverse patterns of cardiovascular mortality require investigation to identify the role of established and new cardiovascular risk factors. Secondary prevention with effective and inexpensive long-term treatment and adult smoking cessation could prevent substantial numbers of premature deaths. Without progress against the control of cardiovascular disease in India, global goals to reduce non-communicable diseases by 2030 will be difficult to achieve. Funding Fogarty International Center of the US National Institutes of Health, Dalla Lana School of Public Health, University of Toronto, Indian Council of Medical Research, and the Disease Control Priorities.
Nationwide mortality studies to quantify causes of death: Relevant lessons from India's million death study
Mireille Gomes, Rehana Begum, Prabha Sati, Rajesh Dikshit, Prakash C. Gupta, Rajesh Kumar, Jay Sheth, Asad Habib, Prabhat Jha
Health Affairs, 2017
Progress toward the United Nations 2030 Sustainable Development Goals requires improved information on mortality and causes of death. However, causes of many of the fifty million annual deaths in low- and middle-income countries remain unknown, as most of the deaths occur at home without medical attention. In 2001 India began the Million Death Study in 1.3 million nationally representative households. Nonmedical staff conduct verbal autopsies, which are structured interviews including a half-page narrative in local language of the family's story of the symptoms and events leading to death. Two physicians independently assess each death to arrive at an underlying cause of death. The study has thus far yielded information that substantially altered previous estimates of cause-specific mortality and risk factors in India. Similar robust studies are feasible at low cost in other low- and middle-income countries, particularly if they adopt electronic data management and ensure high quality of fieldwork and physician coding. Nationwide mortality studies enable the quantification of avoidable premature mortality and key risk factors for disease, and provide a practicable method to monitor progress toward the Sustainable Development Goals.
Changes in cause-specific neonatal and 1–59-month child mortality in India from 2000 to 2015: a nationally representative survey
Shaza A Fadel, Reeta Rasaily, Shally Awasthi, Rehana Begum, Robert E Black, Hellen Gelband, Patrick Gerland, Rajesh Kumar, Li Liu, Colin Mathers, Shaun K Morris, Saritha Nair, Leslie Newcombe, Arvind Pandey, Faujdar Ram, Usha Ram, Peter S Rodriguez, Damodar Sahu, Prabha Sati, Prakash J Shah, Anita Shet, Jay Sheth, Jitenkumar K Singh, Lucky Singh, Anju Sinha, Wilson Suraweera, Prabhat Jha
Lancet, 2017
BACKGROUND Documentation of the demographic and geographical details of changes in cause-specific neonatal (younger than 1 month) and 1-59-month mortality in India can guide further progress in reduction of child mortality. In this study we report the changes in cause-specific child mortality between 2000 and 2015 in India. METHODS Since 2001, the Registrar General of India has implemented the Million Death Study (MDS) in 1·3 million homes in more than 7000 randomly selected areas of India. About 900 non-medical surveyors do structured verbal autopsies for deaths recorded in these homes. Each field report is assigned randomly to two of 404 trained physicians to classify the cause of death, with a standard process for resolution of disagreements. We combined the proportions of child deaths according to the MDS for 2001-13 with annual UN estimates of national births and deaths (partitioned across India's states and rural or urban areas) for 2000-15. We calculated the annual percentage change in sex-specific and cause-specific mortality between 2000 and 2015 for neonates and 1-59-month-old children. FINDINGS The MDS captured 52 252 deaths in neonates and 42 057 deaths at 1-59 months. Examining specific causes, the neonatal mortality rate from infection fell by 66% from 11·9 per 1000 livebirths in 2000 to 4·0 per 1000 livebirths in 2015 and the rate from birth asphyxia or trauma fell by 76% from 9·0 per 1000 livebirths in 2000 to 2·2 per 1000 livebirths in 2015. At 1-59 months, the mortality rate from pneumonia fell by 63% from 11·2 per 1000 livebirths in 2000 to 4·2 per 1000 livebirths in 2015 and the rate from diarrhoea fell by 66% from 9·4 per 1000 livebirths in 2000 to 3·2 per 1000 livebirths in 2015 (with narrowing girl-boy gaps). The neonatal tetanus mortality rate fell from 1·6 per 1000 livebirths in 2000 to less than 0·1 per 1000 livebirths in 2015 and the 1-59-month measles mortality rate fell from 3·3 per 1000 livebirths in 2000 to 0·3 per 1000 livebirths in 2015. By contrast, mortality rates for prematurity or low birthweight rose from 12·3 per 1000 livebirths in 2000 to 14·3 per 1000 livebirths in 2015, driven mostly by increases in term births with low birthweight in poorer states and rural areas. 29 million cumulative child deaths occurred from 2000 to 2015. The average annual decline in mortality rates from 2000 to 2015 was 3·3% for neonates and 5·4% for children aged 1-59 months. Annual declines from 2005 to 2015 (3·4% decline for neonatal mortality and 5·9% decline in 1-59-month mortality) were faster than were annual declines from 2000 to 2005 (3·2% decline for neonatal mortality and 4·5% decline in 1-59-month mortality). These faster declines indicate that India avoided about 1 million child deaths compared with continuation of the 2000-05 declines. INTERPRETATION To meet the 2030 Sustainable Development Goals for child mortality, India will need to maintain the current trajectory of 1-59-month mortality and accelerate declines in neonatal mortality (to >5% annually) from 2015 onwards. Continued progress in reduction of child mortality due to pneumonia, diarrhoea, malaria, and measles at 1-59 months is feasible. Additional attention to low birthweight is required. FUNDING National Institutes of Health, Disease Control Priorities Network, Maternal and Child Epidemiology Estimation Group, and University of Toronto.
Incorporation of dental health screening in paediatric office practice
Pallavi Dagli, Jyotsna Singh, Jay Sheth, Khyati Kakkad
Journal of Nepal Paediatric Society, 2017
Salient features of bio-medical waste management rules, 2016
Indian Journal of Community Health, 2017
Focused group discussion of urban ASHA workers regarding their workrelated issues
Indian Journal of Community Health, 2017
Deaths from acute abdominal conditions and geographical access to surgical care in India: A nationally representative spatial analysis
Anna J Dare, Joshua S Ng-Kamstra, Jayadeep Patra, Sze Hang Fu, Peter S Rodriguez, Marvin Hsiao, Raju M Jotkar, J S Thakur, Jay Sheth, Prabhat Jha
Lancet Global Health, 2015
Performance criteria for verbal autopsy-based systems to estimate national causes of death: Development and application to the Indian Million Death Study
Lukasz Aleksandrowicz, Varun Malhotra, Rajesh Dikshit, Prakash C Gupta, Rajesh Kumar, Jay Sheth, Suresh Kumar Rathi, Wilson Suraweera, Pierre Miasnikof, Raju Jotkar, Dhirendra Sinha, Shally Awasthi, Prakash Bhatia, Prabhat Jha
BMC Medicine, 2014
Road traffic injury mortality and its mechanisms in India: Nationally representative mortality survey of 1.1 million homes
Marvin Hsiao, Ajai Malhotra, J S Thakur, Jay K Sheth, Avery B Nathens, Neeraj Dhingra, Prabhat Jha, and
BMJ Open, 2013
Systemic involvements and fatalities during Chikungunya epidemic in India, 2006
Babasaheb V. Tandale, Padmakar S. Sathe, Vidya A. Arankalle, R.S. Wadia, Rahul Kulkarni, Sudhir V. Shah, Sanjeev K. Shah, Jay K. Sheth, A.B. Sudeep, Anuradha S. Tripathy, Akhilesh C. Mishra
Journal of Clinical Virology, 2009

RECENT SCHOLAR PUBLICATIONS

Antenatal Care Services and its correlation with Outcomes of Pregnancy amongst Beneficiaries in Rural Health Training Center Jetalpur, Ahmedabad
B Davda, S Vyas, M Patel, J Sheth, M Patel
GAIMS Journal of Medical Sciences 5 (1), 147-152 , 2025
2025
Assessing role of HRCT screening policy among COVID-19 test-negative symptomatic patients in Ahmedabad, India.
O Prakash, B Solank, S Patel, D Patel, JK Sheth, P Chaudhary, J Modi
2023
Evaluation of Educational Environment Using the Dundee Ready Educational Environment Measure-12–Abridged version of the Dundee Ready Educational Environment Measure-50 …
A Mehta, K Mehta, N Mistry, V Mehta, S Saiyad, J Sheth
CHRISMED Journal of Health and Research 10 (3), 205-209 , 2023
2023
Citations: 4
An objective overview of Covid-19 vaccine situation in India
J Sheth, K Prasad, T Puwar
Natl. J. Community Med 13 (5), 342-345 , 2022
2022
Citations: 2
COVID-Kavach-Based Seropositivity in the General Population of Ahmedabad: Just Before the Start of the Vaccination for the Elderly in India
O Prakash, B Solanki, JK Sheth, M Nayak, M Kadam, S Vyas, A Shukla, ...
Cureus 14 (3) , 2022
2022
Seroprevalence of Immunoglobulin G Antibody among Contacts of COVID19 Cases: A Study from India
O Prakash, B Solanki, J Sheth, M Acharya, M Kadam, S Vyas, A Shukla, ...
Journal of Health Science and Medical Research 40 (2), 147-155 , 2022
2022
Citations: 1
Immunoglobulin-G antibodies against severe acute respiratory syndrome–coronavirus-2 among health-care workers: A serosurveillance study from India
O Prakash, B Solanki, J Sheth, H Acharya, S Acharya, M Vinzuda, ...
International Journal of Applied and Basic Medical Research 12 (1), 18-23 , 2022
2022
Citations: 1
Seroprevalence of Immunoglobulin-G Antibody Among Confirm Cases of Covid-19
O Prakash, B Solanki, J Sheth, T Shah, M Kadam, S Vyas, A Shukla, ...
Cureus 13 (9), DOI: 10.7759/cureus.17956 , 2021
2021
Citations: 1
SARS-CoV2 IgG antibody: Seroprevalence among health care workers
O Prakash, B Solanki, J Sheth, G Makwana, M Kadam, S Vyas, A Shukla, ...
Clinical Epidemiology and Global Health 11, 100766 , 2021
2021
Citations: 18
Serosurveillance among COVID-19 cases in Ahmedabad using SARS-COV2 IgG antibodies
O Prakash, B Solanki, J Sheth, D Maitrak, M Kadam, S Vyas, A Shukla, ...
Indian Journal of Community Health 33 (2), 351-356 , 2021
2021
Citations: 3
Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city
O Prakash, B Solanki, J Sheth, D Oza, M Kadam, S Vyas, A Shukla, ...
Journal of Family Medicine and Primary Care 10 (6), 2363-2368 , 2021
2021
Citations: 6
Covid-19 Serosurveillance Positivity in General Population: Comparison at Different Times
O Prakash, B Solanki, J Sheth, C Shah, M Kadam, S Vyas, A Shukla, ...
National Journal of Community Medicine 12 (5), 114-119 , 2021
2021
Covid-19 Serosurveillance Positivity in General Population: Comparison at Different Times
O Prakash, B Solanki, JK Sheth, C Shah, M Kadam, S Vyas, A Shukla, ...
National Journal of Community Medicine 12 (5), 114-119 , 2021
2021
Citations: 3
Reassessing the population based seroprevalence for IgG antibodies against SARS COV2 in Ahmedabad
O Prakash, B Solanki, J Sheth, A Kharadi, M Kadam, S Vyas, A Shukla, ...
Asian Journal of Medical Sciences 12 (5), 1-6 , 2021
2021
Citations: 2
High-resolution Computed Tomography Screening Policy among Test Negative Symptomatic in Ahmedabad – A Covid-19 Policy Perspective
B Solanki, J Sheth, S Patel, D Patel
Annals of Community Health 9 (1), 322-326 , 2021
2021
Severe acute respiratory syndrome coronavirus 2 immunoglobulin G antibody: Seroprevalence among contacts of COVID-19 cases
O Prakash, B Solanki, JK Sheth, M Kadam, S Vyas, ...
Indian Journal of Public Health 65 (1), 5-10 , 2021
2021
Citations: 7
Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study
O Prakash, B Solanki, JK Sheth, B Joshi, M Kadam, S Vyas, A Shukla, ...
BMJ Open 11 (1), e044101 , 2021
2021
Citations: 30
Profile of neonates with fever admitted in NICU of a tertiary care teaching hospital: a study to find effect of environmental heat on neonatal aetiology of fever
JS Tamanna Mohta
Indian Journal of Applied Research 10 (9), 75-77 , 2020
2020
Perception of first MBBS students from a medical college in Ahmedabad, Gujarat about one month’s foundation course during the year 2019
S Vyas, U Joshi, J Sheth
Natl J Integr Res Med 11 (1), 72-78 , 2020
2020
Citations: 13
Divergent trends in ischaemic heart disease and stroke mortality in India from 2000 to 2015: a nationally representative mortality study
C Ke, R Gupta, D Xavier, D Prabhakaran, P Mathur, YV Kalkonde, ...
The Lancet Global Health 6 (8), e914-e923 , 2018
2018
Citations: 119

Dr JAY K. SHETH

RESEARCH INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS